MARKET

HUMA

HUMA

Humacyte Inc
NASDAQ
0.7182
+0.0086
+1.21%
After Hours: 0.7247 +0.0065 +0.91% 19:59 08/07 EDT
OPEN
0.7128
PREV CLOSE
0.7096
HIGH
0.7398
LOW
0.7021
VOLUME
2.28M
TURNOVER
--
52 WEEK HIGH
2.755
52 WEEK LOW
0.5469
MARKET CAP
193.65M
P/E (TTM)
-1.2499
1D
5D
1M
3M
1Y
5Y
1D
Amgen (AMGN) Q2 Earnings and Revenues Surpass Estimates
NASDAQ · 4d ago
Weekly Report: what happened at HUMA last week (0727-0731)?
Weekly Report · 5d ago
Humacyte Receives Nasdaq Notice on Bid Price Noncompliance
TipRanks · 07/31 21:31
Buy Rating Reaffirmed on Humacyte as FDA Clears First-in-Human CABG Study; $2 Price Target Maintained
TipRanks · 07/29 11:27
Humacyte Wins FDA IND Clearance For First-In-Human Coronary Bypass Trial; Stock Up
NASDAQ · 07/27 15:16
Humacyte announces FDA acceptance of CTEV IND application
TipRanks · 07/27 12:25
Weekly Report: what happened at HUMA last week (0720-0724)?
Weekly Report · 07/27 10:12
Weekly Report: what happened at HUMA last week (0713-0717)?
Weekly Report · 07/20 10:09
More
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

Webull offers Humacyte Inc stock information, including NASDAQ: HUMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HUMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HUMA stock methods without spending real money on the virtual paper trading platform.